The Use of Compassionate Ivermectin in the Management of Symptomatic Outpatients and Hospitalized Patients with Clinical Diagnosis of Covid-19 at the Centro Medico Bournigal and at the Centro Medico Punta Cana, Grupo Rescue, Dominican Republic, from May 1 to August 10, 2020
José Morgenstern, José N Redondo, Albida De León, Juan Manuel Canela, Nelson Torres Castro, Johnny Tavares, Miguelina Minaya, Óscar López, Ana Castillo, Ana María Plácido, Rafael Peña Cruz, Yudelka Merette, Marlenin Toribio, Juan Asmir Francisco, Santiago Roca
No antiviral has been shown to reduce mortality in SARS-COV-2 patients to date. In the present Retrospective observational study, 3,099 patients with a definitive or highly probable diagnosis of infection due to COVID-19 were evaluated between May 1st to August 10th, 2020, at the Centro Medico Bournigal (CMBO) and the Centro Medico Punta Cana (CMPC), and all received compassionate treatment with Ivermectin and Azithromycin. A total of 2,706 (87.3%) were discharged for outpatient treatment, all with mild severity of the infection. The average between the onset of symptoms and the Emergency Room (ER) visit in outpatients was 3.6 days (Early Treatment). In 2,688 (99.33%) with outpatient treatment, the disease did not progress to warrant further hospitalization and there were no deaths. In 16 (0.59%) with outpatient treatment, it was necessary their subsequent hospitalization to a room without any death. In 2 (0.08%) with outpatient treatment, it was necessary their admission to the Intensive Care Unit (ICU) and 1 (0.04%) patient died. There were 411 (13.3%) patients hospitalized, being admitted at a COVID-19 room with a moderate disease 300 (9.7%) patients of which 3 (1%) died; and with a severe to critical disease were hospitalized in the ICU 111 (3.6%), 34 (30.6%) of whom died. The mortality percentage of patients admitted to the ICU of 30.6% is similar with the percentage found in the literature of 30.9%. Total mortality was 37 (1.2%) patients, which is much lower than that reported in world statistics, which are around 3%, by the time of completion of this study.
References
Cellina, Orsi, Pittino, Toluian, Oliva, Chest computed tomography findings of COVID-19 pneumonia: Pictorialessay with literature review, J Radiol,
doi:10.1007/s11604-020-01010-7Chen, Zhou, Dong, Qu, Gong et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wahan, China: A descriptive study,
doi:10.1016/s0140-6736(20)30211-7Diego, Inhibition of NF-kB mediated inflammation in severe acute respiratory syndrome coronavirus infected mice increases survival, J virol,
doi:10.1128/jvi.02576-13Gandhi, Lynch, Rio, Clinical practice mild or moderate Covid-NEJM
Khater, Das, Reposing ivermectin to inhibit the activity of SARS CoV2 helicase: Possible implications for COVID 19 therapeutics
Moore, June, Cytokine release syndrome in severe COVID-19
Morgenstern, None, J Clin Trials
Morgenstern, Redondo, Leon, Canela, Torres et al., Genomic characterization and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding, Lancet
Pujadas, Chaudhry, Mcbride, Richter, Zhao et al., SARS-CoV-2 viral load predicts COVID-19 mortality
Ratzinger, Haslacher, Poeppl, Hoermann, Kovarik et al., Azithromycin suppresses CD4 (+) T-cell activation by direct modulation of mTOR activity, Sci Rep,
doi:10.1038/srep07438Riccò, Ferraro, Gualerzi, Ranzieri, Henry et al., Point of care diagnostic tests for detecting SARS-CoV-2 antibodies: A systematic review and meta-analysis of real-world data, J Clin Med,
doi:10.3390/jcm9051515Waleed, Kassar, Aref, Afif, Azithromycin promising medicine for COVID-19 in early stage by effecting on mTORC and immune system
Zhang, Xiao, Zhang, Xia, Cao et al., NEJM coagulopathy and antiphospholipid antibodies in patients with Covid-19,
doi:10.1056/nejmc2007575Zhu, Zhang, Li, Yang, Song, A novel coronavirus from patients with pneumonia in china, N England J Med,
doi:10.1056/nejmoa2001017
